Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q1 FY24 results · Apr–Jun 2023
Panacea Biotec reported revenue from operations of ₹129.19 crore (up 16.7% from Q1 FY23) and net profit of ₹10.98 crore for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 129.19 | 110.70 | +16.7% | 128.93 | +0.2% |
| Other income | 6.08 | 12.21 | −50.2% | 15.06 | −59.6% |
| Total income | 135.27 | 122.91 | +10.1% | 143.99 | −6.1% |
| Profit before tax | 13.03 | (51.16) | Turned profit | 18.21 | −28.4% |
| Net profit for the period | 10.98 | (56.14) | Turned profit | (12.68) | Turned profit |
| EPS, basic (₹) | 1.79 | (9.17) | Turned profit | (2.07) | Turned profit |
| Net margin (%) | 8.5 | -50.7 | -9.8 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 89.41 | 61.34 | +45.8% | 75.02 | +19.2% |
| Other income | 3.34 | 6.53 | −48.9% | 10.27 | −67.5% |
| Total income | 92.75 | 67.87 | +36.7% | 85.29 | +8.7% |
| Profit before tax | 1.29 | (74.24) | Turned profit | 5.10 | −74.7% |
| Net profit for the period | 1.29 | (74.24) | Turned profit | (19.69) | Turned profit |
| EPS, basic (₹) | 0.21 | (12.12) | Turned profit | (3.21) | Turned profit |
| Net margin (%) | 1.4 | -121.0 | -26.2 |
Consolidated
- Filed with BSE
- 12 Aug 2023, 17:16 IST
- Board meeting
- 12 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2023, 17:16 IST
- Board meeting
- 12 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE